Quantum BioPharma Ltd.
QNTM
$9.70
-$1.71-14.99%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.01% | 157.06% | |||
| Depreciation & Amortization | 2.76% | 9.02% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.61% | 42.86% | |||
| Operating Income | 3.61% | -42.86% | |||
| Income Before Tax | 51.39% | -11.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 51.39% | -11.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -211.32% | 214.52% | |||
| Net Income | 42.52% | -7.89% | |||
| EBIT | 3.61% | -42.86% | |||
| EBITDA | 3.81% | -44.20% | |||
| EPS Basic | 54.31% | 11.61% | |||
| Normalized Basic EPS | 47.69% | 16.39% | |||
| EPS Diluted | 54.31% | 11.61% | |||
| Normalized Diluted EPS | 47.69% | 16.39% | |||
| Average Basic Shares Outstanding | 25.83% | 22.06% | |||
| Average Diluted Shares Outstanding | 25.83% | 22.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||